Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 2
3(60.0%)
Phase 1
1(20.0%)
Phase 3
1(20.0%)
5Total
Phase 2(3)
Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07176286Phase 2Recruiting

18F-mFBG Cardiac Uptake With Lewy Body Dementia

Role: lead

NCT06965621Phase 2Not Yet Recruiting

18F-mFBG Imaging for Myocardial Sympathetic Innervation

Role: lead

NCT04535193Phase 1Completed

Open-Label Study of 18F-mFBG for Imaging Myocardial Sympathetic Innervation

Role: lead

NCT04724369Phase 3Completed

Open-Label Study of 18F-mFBG for Imaging Neuroblastoma

Role: lead

NCT06233903Phase 2Withdrawn

18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System

Role: lead

All 5 trials loaded